Diagnostic utility of aberrant methylation of tissue factor pathway inhibitor 2 in pure pancreatic juice for pancreatic carcinoma
Open Access
- 1 November 2006
- journal article
- Published by Wiley in Cancer Science
- Vol. 97 (11), 1267-1273
- https://doi.org/10.1111/j.1349-7006.2006.00308.x
Abstract
The tissue factor pathway inhibitor 2 (TFPI-2) is a Kunitz-type serine proteinase inhibitor. Recently, the aberrant methylation of TFPI-2 was detected frequently in pancreatic carcinoma (PCa) tissues but not in normal pancreatic tissues. We analyzed the aberrant methylation of TFPI-2 in the pure pancreatic juice (PPJ) aspirated endoscopically from patients with various pancreatic diseases. Using the highly sensitive methylation-specific polymerase chain reaction (MSP) and quantitative MSP (Q-MSP) assay, we investigated the aberrant methylation of TFPI-2 in nine human PCa cell lines and in the PPJ from patients with PCa, intraductal papillary mucinous neoplasms (IPMN) and chronic pancreatitis (CP). The incidence of aberrant TFPI-2 methylation was seven (77.8%) of nine PCa cell lines by Q-MSP. In cell lines, the expression of TFPI-2 mRNA by quantitative reverse transcription-polymerase chain reaction showed an inverse correlation to the aberrant methylation of TFPI-2. The incidence of aberrant TFPI-2 methylation in the PPJ was 21 (58.3%) of 36 PCa patients, three (17.6%) of 17 IPMN and one (4.8%) of 21 CP by MSP assay. Using a suitable cut-off value of 2.5 according to the receiver operating characteristic curve, the incidence of aberrant TFPI-2 methylation in the PPJ by real-time MSP was 18 (62.1%) of 29 PCa patients, one (5.1%) of 17 IPMN and three (14.3%) of 21 CP, respectively. The incidence of quantitative TFPI-2 hypermethylation in the PPJ with PCa was significantly higher than that with IPMN (P < 0.001) or CP (P < 0.001). Moreover, the aberrant methylation rate of TFPI-2 in the PPJ was 100%, as observed (6/6) in the PCa patients with liver metastasis, and 86.7% (26/30) in stages IVa + IVb of PCa by Q-MSP assay. These results suggest that promoter methylation of TFPI-2 in the PPJ may be a useful marker in the diagnosis and progression of PCa using an endoscopically feasible approach.This publication has 30 references indexed in Scilit:
- Recombinant adeno‐associated virus (rAAV) expressing TFPI‐2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell lineInternational Journal of Cancer, 2005
- A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic CancerNew England Journal of Medicine, 2004
- Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), in human glioma cellsOncogene, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Usefulness of p53 gene mutations in the supernatant of bile for diagnosis of biliary tract carcinoma: comparison with K- ras mutationThe Esophagus, 2002
- K-ras mutations in duodenal aspirate without secretin stimulation for screening of pancreatic and biliary tract carcinomaCancer, 1999
- Regulation of ProMMP-1 and ProMMP-3 Activation by Tissue Factor Pathway Inhibitor-2/Matrix-Associated Serine Protease InhibitorBiochemical and Biophysical Research Communications, 1999
- Detection of K‐ras Point Mutations at Codon 12 in Pancreatic Juice for the Diagnosis of Pancreatic Cancer by Hybridization Protection Assay: A Simple Method for the Determination of the Types of Point MutationsJapanese Journal of Cancer Research, 1996
- Detection of K-ras Point Mutations at Codon 12 in Pure Pancreatic Juice for the Diagnosis of Pancreatic Cancer by PCR-RFLP AnalysisPancreas, 1996
- Identification of K‐ras Oncogene Mutations in the Pure Pancreatic Juice of Patients with Ductal Pancreatic CancersJapanese Journal of Cancer Research, 1993